Hormone Replacement Therapy with Ovarian Cysts
Hormone replacement therapy (HRT) is safe to initiate in postmenopausal women with ovarian cysts, and evidence suggests it may actually reduce cyst prevalence in early postmenopause; use the lowest effective dose of combined estrogen-progestogen for the shortest duration necessary for symptom control.
Safety Profile
The presence of ovarian cysts does not contraindicate HRT initiation. Research demonstrates that HRT does not increase ovarian cyst prevalence—in fact, in early postmenopausal women (ages 40-55), HRT use was associated with a significantly reduced prevalence of ovarian cysts (10.4% vs. 28.6% in non-users) 1. Overall, there is no difference in cyst prevalence between HRT users and non-users (10.5% vs. 12.5%) 1.
Recommended Regimen
For women with an intact uterus:
- Use combined estrogen plus progestogen therapy (conjugated equine estrogen with medroxyprogesterone acetate is the most studied regimen) 2
- Prescribe the lowest effective dose for the shortest possible time 2
- This approach minimizes risks while addressing menopausal symptoms
Key principle: The decision should be based on symptom severity and individual risk factors, not on the presence of ovarian cysts, which are not a contraindication 2.
Risk-Benefit Considerations
When counseling patients, inform them of the established HRT risks 2:
Early risks (first 1-2 years):
- Venous thromboembolism
- Coronary heart disease events
- Stroke
Long-term risks:
- Breast cancer (increases with duration)
- Small increase in ovarian cancer risk (1 additional case per 1,000 users over 5 years) 3
Benefits:
- Effective menopausal symptom relief
- Reduced hip fractures
- Reduced colorectal cancer
For 10,000 women taking estrogen-progestin for 1 year, expect 7 additional CHD events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers, but 6 fewer colorectal cancers and 5 fewer hip fractures 2.
Clinical Approach
Before initiating HRT in a woman with ovarian cysts:
- Characterize the cysts: Use transvaginal ultrasound to assess size, complexity, and features suggesting malignancy
- Check CA-125 if indicated: Though not reliable for differentiating benign from endometriotic cysts, it may help assess malignancy risk 4, 5
- Consider cyst type: Functional cysts (follicular, corpus luteum) often resolve spontaneously and are not affected adversely by HRT 1
Important Caveats
- Do not use HRT to treat ovarian cysts—hormonal therapy shows no significant benefit over expectant management for cyst resolution 4
- Avoid HRT for chronic disease prevention alone—use only for menopausal symptom management 2
- The presence of simple, benign-appearing ovarian cysts should not delay symptom-driven HRT initiation
- If cysts are complex or concerning for malignancy, complete appropriate workup before starting HRT